Metamizol Stada

Metamizole Sodium Monohydrate, the active ingredient in Metamizol Stada, is a pyrazolone presented as an oral dosage form for oral use. It treats pain and fever in adults and children as directed by a healthcare professional.

GNH USA supplies Metamizol Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Stada is a pyrazolone analgesic and antipyretic used to manage pain and fever.

- Acute pain: provides rapid relief of moderate to severe pain. - Post‑operative pain: helps control pain after surgical procedures. - Fever: reduces elevated body temperature associated with infectious or inflammatory conditions.

Metamizol Stada may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Dizziness or light‑headedness - Mild skin rash or itching - Hypotension, especially with rapid intravenous administration - Transient liver enzyme elevation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Aplastic anemia or other bone‑marrow suppression - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylactic or severe allergic reactions - Hepatic failure or severe hepatitis

Before initiating therapy with Metamizol Stada, consider the following precautions. - Blood count monitoring: perform baseline and periodic complete blood counts to detect early signs of agranulocytosis. - Renal or hepatic impairment: use with caution and adjust dosing as clinically indicated. - Known hypersensitivity: avoid in patients with documented allergy to metamizole or other pyrazolones. - Concomitant myelosuppressive drugs: monitor closely for additive bone‑marrow toxicity. - Medical supervision: only use under prescription and regular clinical review. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Metamizol Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Other myelosuppressive agents: heightened risk of severe blood dyscrasias. - ACE inhibitors or diuretics: may potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: potential additive hypersensitivity. - Lithium: possible increase in lithium serum levels. - Antiepileptic drugs: may alter seizure threshold in susceptible individuals.